A review of the state of cervical cancer: updates from prevention to recurrent disease.

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY Current Opinion in Obstetrics & Gynecology Pub Date : 2024-02-01 Epub Date: 2023-10-11 DOI:10.1097/GCO.0000000000000918

Sarah M Crafton, Puja S Venkat, Ritu Salani

{"title":"A review of the state of cervical cancer: updates from prevention to recurrent disease.","authors":"Sarah M Crafton, Puja S Venkat, Ritu Salani","doi":"10.1097/GCO.0000000000000918","DOIUrl":null,"url":null,"abstract":"Purpose of review: To summarize the recent updates in cervical cancer from prevention and early detection to the management of early stage and recurrent disease as well as future areas of exploration.Recent findings: The importance of the human papilloma virus vaccine and screening continue to make an impact in reducing the global burden of cervical cancer. In early-stage, low risk disease, new studies have demonstrated the role of less radical surgery with similar disease related outcomes. Efforts to improve outcomes in locally advanced cervical cancer have been reported. The incorporation of adjuvant chemotherapy, novel agents and checkpoint inhibitors, with the latter impacting disease free survival. In advanced/recurrent disease, the role of immunotherapy continues to make an impact and, in addition to recurrent disease, has now moved to the frontline for patients with programmed cell death ligand 1 expression. Tisotumab vedotin, an antibody drug conjugate, and other novel agents continue to be studied in this setting.Summary: In this review, we discuss prevention measures and the outcomes of recent trials in all stages of cervical cancer. As therapies continue to evolve, ongoing trials and new areas of exploration will continue to identify opportunities to improve survival in cervical cancer.","PeriodicalId":55194,"journal":{"name":"Current Opinion in Obstetrics & Gynecology","volume":" ","pages":"28-33"},"PeriodicalIF":2.2000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GCO.0000000000000918","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To summarize the recent updates in cervical cancer from prevention and early detection to the management of early stage and recurrent disease as well as future areas of exploration.

Recent findings: The importance of the human papilloma virus vaccine and screening continue to make an impact in reducing the global burden of cervical cancer. In early-stage, low risk disease, new studies have demonstrated the role of less radical surgery with similar disease related outcomes. Efforts to improve outcomes in locally advanced cervical cancer have been reported. The incorporation of adjuvant chemotherapy, novel agents and checkpoint inhibitors, with the latter impacting disease free survival. In advanced/recurrent disease, the role of immunotherapy continues to make an impact and, in addition to recurrent disease, has now moved to the frontline for patients with programmed cell death ligand 1 expression. Tisotumab vedotin, an antibody drug conjugate, and other novel agents continue to be studied in this setting.

Summary: In this review, we discuss prevention measures and the outcomes of recent trials in all stages of cervical cancer. As therapies continue to evolve, ongoing trials and new areas of exploration will continue to identify opportunities to improve survival in cervical cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

宫颈癌症现状综述：从预防到复发疾病的最新进展。

综述目的：总结癌症从预防和早期发现到早期和复发疾病的管理的最新进展以及未来的探索领域。最近的发现：人类乳头状瘤病毒疫苗和筛查的重要性继续对减少全球癌症负担产生影响。在早期低风险疾病中，新的研究已经证明了不太激进的手术在类似疾病相关结果中的作用。据报道，为改善局部晚期癌症的预后所做的努力。辅助化疗、新药物和检查点抑制剂的结合，后者影响无病生存。在晚期/复发性疾病中，免疫疗法的作用继续发挥作用，除了复发性疾病外，现在已经转移到程序性细胞死亡配体1表达患者的一线。Tisotumab vedotin，一种抗体-药物偶联物，和其他新的药物继续在这种环境中进行研究。摘要：在这篇综述中，我们讨论了预防措施和最近在癌症所有阶段的试验结果。随着治疗方法的不断发展，正在进行的试验和新的探索领域将继续确定提高宫颈癌症生存率的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Obstetrics & Gynecology 医学-妇产科学

CiteScore

4.10

自引率

0.00%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With eleven disciplines published across the year – including reproductive endocrinology, gynecologic cancer and fertility– every issue also contains annotated references detailing the merits of the most important papers.